由Nlrp12驱动的PANoptosis在Cona诱导的自身免疫性肝炎中加剧了肝损伤
Jun Lin1,2, Kaiyu Feng1,3, Feiyang Wang1,2
1Department of General Surgery, Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, China.
Genes and immunity
|March 2, 2026
概括
Nlrp12通过激活细胞死亡途径PANoptosis来加剧自身免疫性肝炎 (AIH). 抑制Nlrp12或PANoptosis可以减少肝炎和肝损伤,为AIH提供新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 细胞死亡机制 细胞死亡机制
背景情况:
- 自身免疫性肝炎 (AIH) 是一种由异常免疫反应驱动的慢性肝病.
- 细胞死亡的确切机制,特别是AIH病原体中的热,仍然不清楚.
- 损伤相关分子模式 (DAMP) 的传感器Nlrp12,涉及炎症酶激活和热信号传递.
研究的目的:
- 研究NLRP12在自身免疫性肝炎的发展和进展中的作用.
- 在AIH的背景下,阐明Nlrp12调解的特定细胞死亡途径.
- 探索针对AIH中NLRP12-PANoptosis轴的治疗潜力.
主要方法:
- 使用康卡纳瓦林A (ConA) 诱导的AIH小鼠模型.
- 在肝脏组织中评估了NLRP12表达水平.
- 使用了Nlrp12的基因切除和使用RIPK3抑制剂 (GSK-872) 的治疗.
- 评估生存率,血清肝酶,细胞因子水平和肝脏组织学.
主要成果:
- ConA挑战显著增加了Nlrp12在肝脏中的表达.
- 缺乏NLRP12显著改善了生存率,减少了肝损伤标志物,并抑制了炎症.
- 发现NLRP12驱动PANoptosome组合 (ASC,RIPK3,Caspase-8),促进炎症因子的释放.
- 抑制RIPK3有效地阻断了PANoptosome的形成,并减轻了肝损伤.
结论:
- 通过PANoptosis激活,NLRP12在AIH中恶化免疫媒介性肝损伤方面发挥着关键作用.
- Nlrp12-PANoptosis通路代表了对自身免疫性肝炎的一种新且有前途的治疗标.
相关概念视频
01:24Chronic Pancreatitis I: Introduction
906
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
906
01:24Cirrhosis II: Pathophysiology
42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
01:21Acute Pancreatitis II: Pathophysiology
46
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
46
01:25Chronic Pancreatitis I: Introduction
26
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
26
01:21Chronic Pancreatitis II: Pathophysiology
30
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
30